Comparable antibody levels in heterologous and homologous mRNA COVID-19 vaccination, with superior neutralizing and IgA antibody responses in mRNA homologous boosting

Comparable antibody levels in heterologous and homologous mRNA COVID-19 vaccination, with superior neutralizing and IgA antibody responses in mRNA homologous boosting

BackgroundPriming with two doses of AZD1222 (Oxford-AstraZeneca; ChAd) followed by a third mRNA vaccine boosting is considered in several countries, yet comparisons between heterologous and homologous booster efficacy remain unexplored. AimTo evaluate and contrast the immunogenicity of homologous an...

Full description

Saved in:
Bibliographic Details
Main Author: Salma, Younes (author)
Other Authors: Nicolai, Eleonora (author), Younes, Nadin (author), Pieri, Massimo (author), Bernardini, Sergio (author), Nizamuddin, Parveen B. (author), Al-Sadeq, Duaa W. (author), Daas, Hanin I. (author), Ismail, Ahmed (author), Yassine, Hadi M. (author), Abu-Raddad, Laith J. (author), Nasrallah, Gheyath K. (author)
Format: article
Published: 2024
Subjects:
AZD1222 (Oxford-AstraZeneca, ChAd)
Homologous
Heterologous
mRNA vaccination
Neutralizing antibody
Anti-S1 IgA
Online Access:http://dx.doi.org/10.1016/j.vaccine.2024.06.010
https://www.sciencedirect.com/science/article/pii/S0264410X24006698
http://hdl.handle.net/10576/58683
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items